Searched for
ELEPSIA XR
USFDA rules against Sun Pharma Advanced Research Co's appeal regarding cancer drug applicationThe Office of New Drugs (OND) of the US Food and Drug Administration (FDA) has denied the company's appeal of the Complete Response Letter ...- SPARC plunges 10% as USFDA rejects application for cancer drug TaclantisThe company informed this to the exchanges after market hours of Tuesday.
- Sun Pharma arm gets USFDA nod for epilepsy drugThe subsidiary concerned had in-licensed Elepsia XR from Sun Pharma Advanced Research Company (SPARC) in July 2016.
- Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...
- Expect delay in start of royalty from 2 new drugs: SPARCSun Pharma Advanced Research Company (SPARC) expects further delay in start of royalty income from its two new drug applications, including...
- SPARC, Sun Pharma slide as USFDA rescinds approval to drugShares of Sun Pharma Advanced Research Company today fell by almost 3 per cent as the US health regulator has revoked its earlier approval ...
- SPARC, Sun Pharma drop on USFDA revocation of approvalShares of SPARC closed 2.62 per cent lower at Rs 375.80 after hitting the day's low of Rs 368.50 on the exchange. Parent Sum Pharma ended 3...
- Sun Pharma Advanced Research Company shares surge 15 per cent; m-cap up by Rs 1,685 croreStocks of Sun Pharma Advanced Research Company Ltd surged 15 per cent today after the company received approval from the US health regulato...
- SPARC shares settle with 5 per cent gain; market capitalisation up by Rs 440 croreELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients of 12 years of age and older with epi...
- SPARC gets USFDA nod for its anti-epileptic drug ELEPSIA XR"Approval of ELEPSIA XRTM as 1,000 mg and 1,500 mg once a day tablets will be very useful for these patients and physicians."
Load More
